WO2013073968A3 - Agents de modulation de la signalisation cellulaire - Google Patents

Agents de modulation de la signalisation cellulaire Download PDF

Info

Publication number
WO2013073968A3
WO2013073968A3 PCT/NZ2012/000164 NZ2012000164W WO2013073968A3 WO 2013073968 A3 WO2013073968 A3 WO 2013073968A3 NZ 2012000164 W NZ2012000164 W NZ 2012000164W WO 2013073968 A3 WO2013073968 A3 WO 2013073968A3
Authority
WO
WIPO (PCT)
Prior art keywords
modulation
agents
cells
cell signalling
methods
Prior art date
Application number
PCT/NZ2012/000164
Other languages
English (en)
Other versions
WO2013073968A2 (fr
Inventor
Keryn Johnson
Original Assignee
Industrial Research Limited
Meat & Livestock Australia Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2011903730A external-priority patent/AU2011903730A0/en
Application filed by Industrial Research Limited, Meat & Livestock Australia Limited filed Critical Industrial Research Limited
Publication of WO2013073968A2 publication Critical patent/WO2013073968A2/fr
Publication of WO2013073968A3 publication Critical patent/WO2013073968A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des procédés et des peptides permettant de moduler la communication par jonction communicante entre des cellules. Plus particulièrement, la présente invention concerne des procédés permettant de moduler la communication par jonction communicante entre des cellules de mammifère, le procédé comprenant le traitement des cellules avec une quantité efficace d'un peptide possédant la séquence d'acides aminés FHPSS (SEQ ID NO: 3), ou d'une forme variante de celui-ci présentant une identité de séquence d'au moins 60 % avec la séquence d'acides aminés et contenant au moins 4 acides aminés.
PCT/NZ2012/000164 2011-09-12 2012-09-12 Agents de modulation de la signalisation cellulaire WO2013073968A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2011903730 2011-09-12
AU2011903730A AU2011903730A0 (en) 2011-09-12 Agents for modulation of cell signalling

Publications (2)

Publication Number Publication Date
WO2013073968A2 WO2013073968A2 (fr) 2013-05-23
WO2013073968A3 true WO2013073968A3 (fr) 2013-06-20

Family

ID=48430320

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NZ2012/000164 WO2013073968A2 (fr) 2011-09-12 2012-09-12 Agents de modulation de la signalisation cellulaire

Country Status (1)

Country Link
WO (1) WO2013073968A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201512139D0 (en) * 2015-07-10 2015-08-19 Zealand Pharma As Methods of treatment
BR112021004731A2 (pt) * 2018-09-12 2021-09-08 Firststring Research, Inc. Formulações de nanopartículas e métodos de uso para peptídeos de terminal-c alfa conexina.
GB202211043D0 (en) * 2022-07-28 2022-09-14 Univ Birmingham Peptide agonist

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001034629A1 (fr) * 1999-11-12 2001-05-17 Human Genome Sciences, Inc. 21 proteines humaines secretees
WO2006134494A2 (fr) * 2005-02-03 2006-12-21 Coda Therapeutics Limited Composes anti-connexine et leurs utilisations
WO2007033230A2 (fr) * 2005-09-12 2007-03-22 Novimmune S.A. Formulations d'anticorps anti-cd3
WO2009010733A2 (fr) * 2007-07-15 2009-01-22 Zealand Pharma A/S Modulateurs peptidiques des jonctions lacunaires
WO2009029991A1 (fr) * 2007-09-07 2009-03-12 Meat & Livestock Australia Limited Agents présentant une activité angiogénique et de guérison de plaies
WO2012175741A2 (fr) * 2011-06-23 2012-12-27 Ablynx Nv Techniques permettant de prédire, détecter et réduire une interférence protéinique spécifique dans des dosages impliquant des domaines variables uniques d'immunoglobuline
WO2013003647A2 (fr) * 2011-06-28 2013-01-03 Sea Lane Biotechnologies, Llc Protéines de liaison à domaines variables empilés polyvalentes

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001034629A1 (fr) * 1999-11-12 2001-05-17 Human Genome Sciences, Inc. 21 proteines humaines secretees
WO2006134494A2 (fr) * 2005-02-03 2006-12-21 Coda Therapeutics Limited Composes anti-connexine et leurs utilisations
WO2007033230A2 (fr) * 2005-09-12 2007-03-22 Novimmune S.A. Formulations d'anticorps anti-cd3
WO2009010733A2 (fr) * 2007-07-15 2009-01-22 Zealand Pharma A/S Modulateurs peptidiques des jonctions lacunaires
WO2009029991A1 (fr) * 2007-09-07 2009-03-12 Meat & Livestock Australia Limited Agents présentant une activité angiogénique et de guérison de plaies
WO2012175741A2 (fr) * 2011-06-23 2012-12-27 Ablynx Nv Techniques permettant de prédire, détecter et réduire une interférence protéinique spécifique dans des dosages impliquant des domaines variables uniques d'immunoglobuline
WO2013003647A2 (fr) * 2011-06-28 2013-01-03 Sea Lane Biotechnologies, Llc Protéines de liaison à domaines variables empilés polyvalentes

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LI Y-W. ET AL.: "Structure-activity relationship study of antioxidant peptides by QSAR modeling: the amino acid next to C-terminus affects the activity", JOURNAL OF PEPTIDE SCIENCE, vol. 17, no. 6, June 2011 (2011-06-01), pages 454 - 462 *
POOJARY B. ET AL.: "Synthetic studies on cyclic octapeptides: Yunnanin F and Hymenistatin", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 40, no. 4, 2005, pages 407 - 412 *

Also Published As

Publication number Publication date
WO2013073968A2 (fr) 2013-05-23

Similar Documents

Publication Publication Date Title
UA110599C2 (uk) Пептид для імунотерапії пухлин, включаючи нейрональні пухлини та пухлини мозку
MX360208B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX360211B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX2014011459A (es) Proteinas nutritivas cargadas y metodos.
CO6491059A2 (es) Diferenciacion de las celulas madre mesenquimales
WO2014202616A3 (fr) Gène de rasamsonia et son utilisation
MX2020010399A (es) 3-epimerasa.
UA103216C2 (uk) Поліпептид з ксиланазною активністю
EP2532366A4 (fr) Composition pharmaceutique pour le traitement et/ou la prévention du cancer
WO2012045082A3 (fr) Synthèse d'acides nucléiques et méthodes d'utilisation associées
NZ701125A (en) Improved chymosine enzyme variants
EA201000327A1 (ru) Белок
NZ602845A (en) Inhibiting peptides derived from trem-like transcript 1 (tlt-1) and uses thereof
MX2014011614A (es) Fragmentos y proteinas nutritivas con fenilalanina baja o nula y metodos.
MX2015003310A (es) Moleculas de union il-17a novedosas y usos medicos de las mismas.
MX2015007421A (es) Proteinas de tipo espiral enrollada modificadas que tienen propiedades mejoradas.
NZ586074A (en) LCLRP peptides, constructs and uses thereof
WO2013073968A3 (fr) Agents de modulation de la signalisation cellulaire
MX2015001542A (es) Metodo.
IN2014DN09963A (fr)
MY187334A (en) Xylanase
AR119056A2 (es) Péptido de fusión, polinucleótido que lo codifica, vector y célula transformada
NZ600818A (en) Cyclic peptides for the regulation of vectorial ion channels
NZ709120A (en) Beta-hexosyl-transferases and uses thereof
WO2012031103A3 (fr) Inhibiteurs de bcl-2

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12850121

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 12850121

Country of ref document: EP

Kind code of ref document: A2